Compare RHP & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHP | BIO |
|---|---|---|
| Founded | 1991 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.9B |
| IPO Year | 1997 | N/A |
| Metric | RHP | BIO |
|---|---|---|
| Price | $115.12 | $312.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $112.60 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 594.0K | 471.8K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $1,184,719,000.00 | N/A |
| Revenue This Year | $9.50 | $2.74 |
| Revenue Next Year | $4.38 | $3.20 |
| P/E Ratio | $112.50 | ★ $9.72 |
| Revenue Growth | ★ 3.09 | N/A |
| 52 Week Low | $83.82 | $211.43 |
| 52 Week High | $116.67 | $343.12 |
| Indicator | RHP | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 69.62 | 68.29 |
| Support Level | $90.34 | $293.88 |
| Resistance Level | N/A | $330.54 |
| Average True Range (ATR) | 2.55 | 9.86 |
| MACD | 0.42 | 6.66 |
| Stochastic Oscillator | 84.46 | 90.63 |
Ryman Hospitality Properties Inc is a lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and country music entertainment experiences. Its core holdings are Gaylord Opryland Resort & Convention Center; Gaylord Palms Resort & Convention Center; Gaylord Texan Resort & Convention Center; Gaylord National Resort & Convention Center; and Gaylord Rockies Resort & Convention Center. The company has three business segments: Hospitality, which includes Gaylord Hotels properties, the Inn at Opryland, and the AC Hotel, Entertainment which includes the entertainment and media assets comprising OEG, and Corporate and Other, which includes corporate expenses. It derives the vast majority of its revenue from its Hospitality segment.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.